Healius Ltd
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patie… Read more
Healius Ltd (HLS) - Net Assets
Latest net assets as of December 2025: AU$557.10 Million AUD
Based on the latest financial reports, Healius Ltd (HLS) has net assets worth AU$557.10 Million AUD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.77 Billion) and total liabilities (AU$1.22 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$557.10 Million |
| % of Total Assets | 31.41% |
| Annual Growth Rate | 12.32% |
| 5-Year Change | -68.35% |
| 10-Year Change | -75.78% |
| Growth Volatility | 69.9 |
Healius Ltd - Net Assets Trend (1998–2025)
This chart illustrates how Healius Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Healius Ltd (1998–2025)
The table below shows the annual net assets of Healius Ltd from 1998 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$587.90 Million | -43.51% |
| 2024-06-30 | AU$1.04 Billion | -30.91% |
| 2023-06-30 | AU$1.51 Billion | -21.62% |
| 2022-06-30 | AU$1.92 Billion | +3.46% |
| 2021-06-30 | AU$1.86 Billion | -3.83% |
| 2020-06-30 | AU$1.93 Billion | -5.84% |
| 2019-06-30 | AU$2.05 Billion | +12.77% |
| 2018-06-30 | AU$1.82 Billion | -2.69% |
| 2017-06-30 | AU$1.87 Billion | -23.01% |
| 2016-06-30 | AU$2.43 Billion | +0.51% |
| 2015-06-30 | AU$2.42 Billion | +1.87% |
| 2014-06-30 | AU$2.37 Billion | -11.49% |
| 2013-06-30 | AU$2.68 Billion | +4.11% |
| 2012-06-30 | AU$2.57 Billion | +2.74% |
| 2011-06-30 | AU$2.50 Billion | +1.38% |
| 2010-06-30 | AU$2.47 Billion | +16.70% |
| 2009-06-30 | AU$2.12 Billion | +20.19% |
| 2008-06-30 | AU$1.76 Billion | +330.17% |
| 2007-06-30 | AU$409.41 Million | +4.33% |
| 2006-06-30 | AU$392.42 Million | +22.62% |
| 2005-06-30 | AU$320.01 Million | +61.17% |
| 2004-06-30 | AU$198.55 Million | +6.59% |
| 2003-06-30 | AU$186.29 Million | +7.97% |
| 2002-06-30 | AU$172.54 Million | +54.98% |
| 2001-06-30 | AU$111.33 Million | +0.98% |
| 2000-06-30 | AU$110.25 Million | +134.54% |
| 1999-06-30 | AU$47.01 Million | +84.29% |
| 1998-06-30 | AU$25.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Healius Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 420921.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$2.60 Billion | 442.93% |
| Other Comprehensive Income | AU$300.00K | 0.05% |
| Total Equity | AU$587.90 Million | 100.00% |
Healius Ltd Competitors by Market Cap
The table below lists competitors of Healius Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Marr S.p.A.
LSE:0NSS
|
$208.83 Million |
|
Alar Pharmaceuticals Inc.
TWO:6785
|
$208.85 Million |
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
$208.89 Million |
|
Grupo Clarin S.A.
BA:GCLA
|
$208.91 Million |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
$208.77 Million |
|
Chongqing Yukaifa Co Ltd
SHE:000514
|
$208.71 Million |
|
Tyro Payments Ltd
AU:TYR
|
$208.71 Million |
|
Yamashin-Filter Corp
PINK:YMFCF
|
$208.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Healius Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,040,700,000 to 587,900,000, a change of -452,800,000 (-43.5%).
- Net loss of 151,200,000 reduced equity.
- Dividend payments of 299,900,000 reduced retained earnings.
- Other comprehensive income decreased equity by 3,800,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-151.20 Million | -25.72% |
| Dividends Paid | AU$299.90 Million | -51.01% |
| Other Comprehensive Income | AU$-3.80 Million | -0.65% |
| Other Changes | AU$2.10 Million | +0.36% |
| Total Change | AU$- | -43.51% |
Book Value vs Market Value Analysis
This analysis compares Healius Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 11.87x to 0.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-06-30 | AU$0.05 | AU$0.59 | x |
| 1999-06-30 | AU$0.09 | AU$0.59 | x |
| 2000-06-30 | AU$1.06 | AU$0.59 | x |
| 2001-06-30 | AU$0.94 | AU$0.59 | x |
| 2002-06-30 | AU$1.40 | AU$0.59 | x |
| 2003-06-30 | AU$1.34 | AU$0.59 | x |
| 2004-06-30 | AU$1.40 | AU$0.59 | x |
| 2005-06-30 | AU$2.02 | AU$0.59 | x |
| 2006-06-30 | AU$2.29 | AU$0.59 | x |
| 2007-06-30 | AU$2.32 | AU$0.59 | x |
| 2008-06-30 | AU$5.67 | AU$0.59 | x |
| 2009-06-30 | AU$4.98 | AU$0.59 | x |
| 2010-06-30 | AU$4.81 | AU$0.59 | x |
| 2011-06-30 | AU$4.51 | AU$0.59 | x |
| 2012-06-30 | AU$4.59 | AU$0.59 | x |
| 2013-06-30 | AU$4.75 | AU$0.59 | x |
| 2014-06-30 | AU$4.19 | AU$0.59 | x |
| 2015-06-30 | AU$4.70 | AU$0.59 | x |
| 2016-06-30 | AU$4.16 | AU$0.59 | x |
| 2017-06-30 | AU$3.20 | AU$0.59 | x |
| 2018-06-30 | AU$3.48 | AU$0.59 | x |
| 2019-06-30 | AU$3.13 | AU$0.59 | x |
| 2020-06-30 | AU$2.87 | AU$0.59 | x |
| 2021-06-30 | AU$2.74 | AU$0.59 | x |
| 2022-06-30 | AU$3.05 | AU$0.59 | x |
| 2023-06-30 | AU$2.45 | AU$0.59 | x |
| 2024-06-30 | AU$1.58 | AU$0.59 | x |
| 2025-06-30 | AU$0.81 | AU$0.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Healius Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.25%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 3.02x
- Recent ROE (-25.72%) is below the historical average (-0.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 8.95% | 0.00% | 0.00x | 1.58x | AU$-268.83K |
| 1999 | 8.78% | 0.00% | 0.00x | 1.83x | AU$-572.90K |
| 2000 | 4.93% | 8.64% | 0.39x | 1.47x | AU$-5.59 Million |
| 2001 | 5.68% | 7.05% | 0.41x | 1.98x | AU$-4.81 Million |
| 2002 | 3.67% | 6.15% | 0.36x | 1.64x | AU$-10.92 Million |
| 2003 | 6.76% | 9.93% | 0.43x | 1.57x | AU$-6.04 Million |
| 2004 | 9.09% | 11.99% | 0.50x | 1.52x | AU$-1.81 Million |
| 2005 | 8.73% | 14.11% | 0.44x | 1.40x | AU$-4.07 Million |
| 2006 | 12.10% | 19.72% | 0.44x | 1.39x | AU$8.24 Million |
| 2007 | 13.91% | 20.98% | 0.45x | 1.48x | AU$16.00 Million |
| 2008 | 0.39% | 1.04% | 0.14x | 2.73x | AU$-168.94 Million |
| 2009 | 5.13% | 8.17% | 0.35x | 1.79x | AU$-102.81 Million |
| 2010 | 5.35% | 10.26% | 0.35x | 1.50x | AU$-114.58 Million |
| 2011 | 3.13% | 5.98% | 0.34x | 1.53x | AU$-171.65 Million |
| 2012 | 4.54% | 8.38% | 0.36x | 1.50x | AU$-140.16 Million |
| 2013 | 5.61% | 10.31% | 0.37x | 1.49x | AU$-117.60 Million |
| 2014 | 6.86% | 10.66% | 0.41x | 1.58x | AU$-74.40 Million |
| 2015 | 5.28% | 7.90% | 0.41x | 1.62x | AU$-113.86 Million |
| 2016 | 1.58% | 2.38% | 0.45x | 1.49x | AU$-204.21 Million |
| 2017 | -27.67% | -31.16% | 0.53x | 1.67x | AU$-703.56 Million |
| 2018 | 0.23% | 0.24% | 0.56x | 1.72x | AU$-177.79 Million |
| 2019 | 2.70% | 3.53% | 0.47x | 1.63x | AU$-149.81 Million |
| 2020 | -3.65% | -4.45% | 0.35x | 2.38x | AU$-263.63 Million |
| 2021 | 2.35% | 2.30% | 0.50x | 2.04x | AU$-142.03 Million |
| 2022 | 16.02% | 13.45% | 0.55x | 2.15x | AU$115.74 Million |
| 2023 | -24.42% | -21.55% | 0.47x | 2.43x | AU$-518.42 Million |
| 2024 | -62.05% | -36.98% | 0.59x | 2.87x | AU$-749.87 Million |
| 2025 | -25.72% | -11.25% | 0.76x | 3.02x | AU$-209.99 Million |
Industry Comparison
This section compares Healius Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $61,617,063
- Average return on equity (ROE) among peers: -24.50%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Healius Ltd (HLS) | AU$557.10 Million | 8.95% | 2.18x | $208.81 Million |
| Australian Clinical Labs Ltd (ACL) | $68.99 Million | 59.80% | 4.31x | $217.50 Million |
| Bcal Diagnostics Ltd (BDX) | $6.22 Million | -116.40% | 0.59x | $10.33 Million |
| Capitol Health Ltd (CAJ) | $144.04 Million | 0.60% | 0.82x | $222.66 Million |
| Cryosite Ltd (CTE) | $1.45 Million | 126.98% | 12.60x | $5.03 Million |
| Genetic Signatures Ltd (GSS) | $16.18 Million | -10.68% | 0.02x | $8.20 Million |
| Inoviq Ltd (IIQ) | $2.83 Million | -115.42% | 0.16x | $23.33 Million |
| Microba Life Sciences Ltd (MAP) | $32.49 Million | -45.98% | 0.46x | $10.42 Million |
| Monash Ivf Group Ltd (MVF) | $268.44 Million | 9.37% | 0.33x | $116.82 Million |
| Pacific Edge Ltd (PEB) | $13.91 Million | -128.81% | 0.19x | $89.67 Million |